JOURNAVX Drug Patent Profile
✉ Email this page to a colleague
When do Journavx patents expire, and when can generic versions of Journavx launch?
Journavx is a drug marketed by Vertex Pharms Inc and is included in one NDA. There is one patent protecting this drug.
This drug has forty patent family members in thirty-five countries.
The generic ingredient in JOURNAVX is suzetrigine. Two suppliers are listed for this compound. Additional details are available on the suzetrigine profile page.
DrugPatentWatch® Generic Entry Outlook for Journavx
Journavx will be eligible for patent challenges on January 30, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for JOURNAVX
JOURNAVX is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of JOURNAVX is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | JOURNAVX | suzetrigine | TABLET;ORAL | 219209-001 | Jan 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Vertex Pharms Inc | JOURNAVX | suzetrigine | TABLET;ORAL | 219209-001 | Jan 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for JOURNAVX
See the table below for patents covering JOURNAVX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 120680 | ⤷ Start Trial | |
| Australia | 2020397059 | ⤷ Start Trial | |
| Brazil | 112022010924 | ⤷ Start Trial | |
| Canada | 3164134 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch